Tüdőrák: vizsgálatok itt: Spanyolország
256 of 275 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peoplePhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Where
- Barcelona, Madrid, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 623 worldwide
- Run by
- Institut de Recherches Internationales Servier
See details and how to joinNCT05786924 · EU 2025-523474-16-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Madrid, Málaga, Seville, Valencia
- Életkor
- 18 év and over
- People
- 890 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1/2. fázisTaking peopleA Phase 1/2 Study of IAM1363 in HER2 Cancers
- Where
- Barcelona, Madrid, Málaga, Seville, Valencia
- Életkor
- 18 év and over
- People
- 463 worldwide
- Run by
- Iambic Therapeutics, Inc
See details and how to joinNCT06253871 · EU 2024-519188-17-00 - 3. fázisTaking peoplePembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Where
- Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Santiago de Compostela, Sevilla
- Életkor
- 18 év and over
- People
- 851 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00 - 3. fázisTaking peopleA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Pozuelo de Alarcón
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00 - 3. fázisTaking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Palma, Santiago de Compostela, Sevilla, Valencia, Vigo
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - 2. fázisNot yet taking people in SpanyolországA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- Where
- Barcelona, Logroño, Madrid
- Életkor
- 18 év and over
- People
- 105 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT07659782 · EU 2026-526472-23-00 - 1. fázisTaking peopleLong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
- Where
- Sevilla
- People
- 12 worldwide
- Run by
- USWM Ct LLC
See details and how to join2024-513033-21-00 - 2. fázisNot yet taking people in SpanyolországA phase II clinical trial of neoadjuvant treatment with Ivonescimab and chemotherapy for stage IIA-IIB-IIIA and IIIB (T3N2) non-small cell lung cancer (NSCLC) patients
- Where
- Alicante, Badalona, Barakaldo, Barcelona, Bilbao, Castello De La Plana, Elche, Girona, Granada, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Palma, Sabadell, Salamanca, Sevilla, Valencia, Valladolid
- Életkor
- 18 év and over
- People
- 49 worldwide
- Run by
- Fundacion GECP
See details and how to join2026-525303-27-00 - 3. fázisNot yet taking people in SpanyolországA Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
- Where
- A Coruña, Badajoz, Barcelona, Girona, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Sevilla, Valencia, Vigo, Zaragoza
- Életkor
- 18 év and over
- People
- 183 worldwide
- Run by
- Summit Therapeutics Inc.
See details and how to join2026-526300-67-00 - 3. fázisTaking peopleLUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Where
- Barcelona, Elche, Lleida, Madrid, Málaga, Pamplona, Seville, Torrejón de Ardoz
- Életkor
- 18 év and over
- People
- 734 worldwide
- Run by
- NovoCure GmbH
See details and how to joinNCT06216301 - 2/3. fázisTaking peopleA Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Where
- Badalona, Barcelona, Castello De La Plana, Girona, Jerez de la Frontera, Madrid, Málaga, Manresa, Ourense, Palma, Zaragoza
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00 - 3. fázisTaking peopleMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Where
- Barcelona, Girona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Pozuelo de Alarcón, Sevilla
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00 - 3. fázisTaking peopleA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Badajoz, Barakaldo, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00 - 2. fázisNot yet taking people in SpanyolországAn international study evaluating diagnostic and theranostic agents in patients with solid tumors and brain metastases.
- Where
- Granada, Madrid, Málaga, Murcia, Pamplona
- Életkor
- 18 év and over
- People
- 66 worldwide
- Run by
- Medica Scientia Innovation Research S.L.
See details and how to join2025-523824-39-01 - 1. fázisTaking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Barcelona, Castello De La Plana, L'Hospitalet de Llobregat, Madrid, Málaga, Pozuelo de Alarcón, Valencia
- Életkor
- 18 év and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - 3. fázisTaking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- A Coruña, Badajoz, Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Oviedo, Palma, Santander, Sevilla, Valencia, Valladolid
- Életkor
- 18 év to 100 év
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - 2. fázisTaking peopleSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Where
- Barcelona, L'Hospitalet de Llobregat, Pozuelo de Alarcón, Sevilla
- Életkor
- 18 év and over
- People
- 144 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780098 · EU 2024-518839-11-00 - 2/3. fázisTaking peopleA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00 - 1/2. fázisTaking peopleA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Where
- Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Málaga, Pamplona, Sevilla, Torrejón de Ardoz, Valencia
- Életkor
- 18 év and over
- People
- 880 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07111520 · EU 2024-519344-32-00 - 1. fázisFut, nem toborozBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Valencia
- Életkor
- 18 év and over
- People
- 554 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00 - 1/2. fázisFut, nem toborozFirst in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 430 worldwide
- Run by
- Bayer
See details and how to joinNCT05099172 · EU 2023-503795-24-00 - 3. fázisTaking peopleImmunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
- Where
- Barcelona, Majadahonda, Valencia
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT05522660 - 1. fázisTaking peopleA Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Logroño, Madrid
- Életkor
- 18 év and over
- People
- 124 worldwide
- Run by
- Pliant Therapeutics, Inc.
See details and how to joinNCT06270706 - 3. fázisTaking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Barcelona, Las Palmas de Gran Canaria, Leganés, Madrid, Málaga, Sevilla, Vic
- Életkor
- 18 év and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00